legacy12159_breast_cancer

Published: 10 January 2022| Version 1 | DOI: 10.17632/ch24bpf65r.1
Contributors:
Felipe Batalini,

Description

Breast cancer cohort from the Phase 1b trial (NCT01623349). Eligible patients had recurrent triple-negative breast cancer (TNBC), or recurrent breast cancer of any subtype with a germline BRCA mutation and were enrolled to a dose escalation or expansion cohort.

Files

Steps to reproduce

Sequencing methods (Oncopanel) per described in Shol et al JCI Insight https://doi.org/10.1172/jci.insight.87062.

Institutions

Harvard Medical School

Categories

Clinical Research

License